ADMA Biologics
ADMA | NASDAQ
$13.47
-$0.21 (-1.54%)
At close: Nov 16, 2026, 4:00 PM ET
$13.74
+$0.27 (+2.03%)
After-hours:
Nov 16, 2026, 7:55 PM ET
ADMA Biologics Company Profile
Company profile explainedCompany Profile
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer & Director |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance |
| Terence Kohler | Chief Financial Officer & Treasurer |
| Jerrold Grossman | Co-Founder & Vice Chairman of the Board |
| John Hafl | Executive Director of Sales |
| Michael Goldstein | General Counsel |
| Skyler Bloom | Senior Director of Business Development & Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 28, 2026 | 4 | Filing |
| Jul 17, 2026 | 4 | Filing |
| Jun 02, 2026 | 8-K | Current Report |
| May 28, 2026 | 4 | Filing |
| May 14, 2026 | 4 | Filing |
| May 12, 2026 | 4 | Filing |
| May 06, 2026 | 10-Q | Quarterly Report |
ADMA Biologics
| Country | United States |
| IPO Date | Oct 17, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 644 |
| CEO | Adam S. Grossman |
Contact Details
465 State Route 17 Ramsey,
New Jersey 07446 United States
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| SIC Code | 2836 |
Recent News
- 3 days ago / zacks.comHere's Why Adma Biologics (ADMA) is a Strong Momentum Stock
- 5 days ago / zacks.comWhy Adma Biologics (ADMA) is a Top Growth Stock for the Long-Term
- 5 days ago / zacks.comADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
- 11 days ago / zacks.comAdma Biologics (ADMA) Just Overtook the 20-Day Moving Average
- 11 days ago / zacks.comAdma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
- 12 days ago / seekingalpha.comADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comAdma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
- 12 days ago / marketbeat.comADMA Biologics Q3 Earnings Call Highlights
- 17 days ago / zacks.comAdma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
- 19 days ago / zacks.comBrokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Add to Watchlist
Select watchlists to add or remove ADMA